New Launch14 Jan 2026, 04:41 pm
Dr. Reddy’s launches first-to-market OTC Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S.
AI Summary
Dr. Reddy’s Laboratories Ltd. has announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra Strength Pataday® Once-Daily Relief, in the U.S. market. This launch adds to Dr. Reddy’s current portfolio in the OTC eye-care space and is a testament to the company's deep capabilities in bringing store-brand equivalents of OTC brands in the U.S. market. The Pataday® brand had U.S. sales of approximately $69.9 million for the latest 52 weeks period ending December 27, 2025.
Key Highlights
- Dr. Reddy’s launches first-to-market OTC Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S.
- Launch adds to Dr. Reddy’s current portfolio in the OTC eye-care space
- Dr. Reddy’s has deep capabilities in bringing store-brand equivalents of OTC brands in the U.S. market
- Pataday® brand had U.S. sales of approximately $69.9 million for the latest 52 weeks period ending December 27, 2025